Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylation

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 23519-23536

  Li, Kehan ^a   Yang, Jianxue ^a   Han, Xuechang ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Breast cancer cells; Cisplatin; DNA demethylation; Lidocaine

Indexed keywords

CASPASE 3; CISPLATIN; LIDOCAINE; MESSENGER RNA; RARB2 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE SEQUENCE; GENOMICS; HUMAN; HUMAN CELL; MTT ASSAY; PROMOTER REGION; PROTEIN ISOLATION; RAS ASSOCIATION DOMAIN FAMILY 1A GENE; RETINOIC ACID RECEPTOR BETA 2 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL SURVIVAL; DNA METHYLATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIDOCAINE; MCF-7 CELLS; RECEPTORS, RETINOIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 84919458490     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151223519     Document Type: Article

References (63)

1. Lambert, L.A.; Lambert, D.H.; Strichartz, G.R. Irreversible conduction block in isolated nerve by high concentrations of local anesthetics. Anesthesiology 1994, 80, 1082–1093.
2. Rigler, M.L.; Drasner, K.; Krejcie, T.C.; Yelich, S.J.; Scholnick, F.T.; DeFontes, J.; Bohner, D. Cauda equina syndrome after continuous spinal anesthesia. Anesth. Analg. 1991, 72, 275–281.
3. Kasaba, T.; Onizuka, S.; Takasaki, M. Procaine and mepivacaine have less toxicity in vitro than other clinically used local anesthetics. Anesth. Analg. 2003, 97, 85–90.
4. Onizuka, S.; Takasaki, M.; Syed, N.I. Long-term exposure to local but not inhalation anesthetics affects neurite regeneration and synapse formation between identified lymnaea neurons. Anesthesiology 2005, 102, 353–363.
5. Werdehausen, R.; Braun, S.; Essmann, F.; Schulze-Osthoff, K.; Walczak, H.; Lipfert, P.; Stevens, M.F. Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. Anesthesiology 2007, 107, 136–143.
6. Johnson, M.E.; Uhl, C.B.; Spittler, K.H.; Wang, H.; Gores, G.J. Mitochondrial injury and caspase activation by the local anesthetic lidocaine. Anesthesiology 2004, 101, 1184–1194.
7. Onizuka, S.; Tamura, R.; Hosokawa, N.; Kawasaki, Y.; Tsuneyoshi, I. Local anesthetics depolarize mitochondrial membrane potential by intracellular alkalization in rat dorsal root ganglion neurons. Anesth. Analg. 2010, 111, 775–783.
8. Onizuka, S.; Yonaha, T.; Tamura, R.; Kasiwada, M.; Shirasaka, T.; Tsuneyoshi, I. Lidocaine depolarizes the mitochondrial membrane potential by intracellular alkalization in rat dorsal root ganglion neurons. J. Anesth. 2011, 25, 229–239.
9. Chang, Y.C.; Liu, C.L.; Chen, M.J.; Hsu, Y.W.; Chen, S.N.; Lin, C.H.; Chen, C.M.; Yang, F.M.; Hu, M.C. Local anesthetics induce apoptosis in human breast tumor cells. Anesth. Analg. 2014, 118, 116–124.
10. Yagiela, J.A.; Benoit, P.W.; Fort, N.F. Mechanism of epinephrine enhancement of lidocaine-induced skeletal muscle necrosis. J. Dent. Res. 1982, 61, 686–690.
11. Lawrence, V.S.; Marte, E.; Brown, B.W.; van Bergen, F.H. Lidocaine, 2-chlorprocaine and hepatic necrosis. Anesth. Analg. 1966, 45, 55–58.
12. Onizuka, S.; Tamura, R.; Yonaha, T.; Oda, N.; Kawasaki, Y.; Shirasaka, T.; Shiraishi, S.; Tsuneyoshi, I. Clinical dose of lidocaine destroys the cell membrane and induces both necrosis and apoptosis in an identified Lymnaea neuron. J. Anesth. 2012, 26, 54–61.
13. Arrebola, F.; Zabiti, S.; Canizares, F.J.; Cubero, M.A.; Crespo, P.V.; Fernandez-Segura, E. Changes in intracellular sodium, chlorine, and potassium concentrations in staurosporine-induced apoptosis. J. Cell Physiol. 2005, 204, 500–507.
14. Belaud-Rotureau, M.A.; Leducq, N.; Macouillard, P.D.G.F.; Diolez, P.; Lacoste, L.; Lacombe, F.; Bernard, P.; Belloc, F. Early transitory rise in intracellular pH leads to Bax conformation change during ceramide-induced apoptosis. Apoptosis 2000, 5, 551–560.
15. Karpie, J.C.; Chu, C.R. Lidocaine exhibits dose- and time-dependent cytotoxic effects on bovine articular chondrocytes in vitro. Am. J. Sports Med. 2007, 35, 1621–1627.
16. Rademaker, A.W.; Kellen, J.; Tam, Y.K.; Wyse, D.G. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin. Pharmacol. Ther. 1986, 40, 71–80.
17. Lewandowska, J.; Bartoszek, A. DNA methylation in cancer development, diagnosis and therapy—Multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. Mutagenesis 2011, 26, 475–487.
18. Kubicek, S.; Schotta, G.; Lachner, M.; Sengupta, R.; Kohlmaier, A.; Perez-Burgos, L.; Linderson, Y.; Martens, J.H.; OʼSullivan, R.J.; Fodor, B.D. et al. The role of histone modifications in epigenetic transitions during normal and perturbed development. Ernst Scher. Res. Found. Workshop 2006, 57, 1–27.
19. Ushijima, T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5, 223–231.
20. Singal, R.; Ginder, G.D. DNA methylation. Blood 1999, 93, 4059–4070.
21. Van Engeland, M.; Weijenberg, M.P.; Roemen, G.M.; Brink, M.; de Bruine, A.P.; Goldbohm, R.A.; vanden Brandt, P.A.; Baylin, S.B.; de Goeij, A.F.; Herman, J.G. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: The Netherlands cohort study on diet and cancer. Cancer Res. 2003, 63, 3133–3137.
22. Vaissiere, T.; Hung, R.J.; Zaridze, D.; Moukeria, A.; Cuenin, C.; Fasolo, V.; Ferro, G.; Paliwal, A.; Hainaut, P.; Brennan, P. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009, 69, 243–252.
23. Villar-Garea, A.; Fraga, M.F.; Espada, J.; Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63, 4984–4989.
24. Tada, M.; Imazeki, F.; Fukai, K.; Sakamoto, A.; Arai, M.; Mikata, R.; Tokuhisa, T.; Yokosuka, O. Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hepatol. Int. 2007, 1, 355–364.
25. Lirk, P.; Berger, R.; Hollmann, M.W.; Fiegl, H. Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. Br. J. Anaesth. 2012, 109, 200–207.
26. Hong, D.Y.; Kwon, K.; Lee, K.R.; Choi, Y.J.; Goo, T.W.; Yu, K.; Kim, S.W.; Kwon, O.Y. Lidocaine induces endoplasmic reticulum stress-associated apoptosis in vitro and in vivo. Int. J. Mol. Sci. 2011, 12, 7652–7661.
27. Sirchia, S.M.; Ren, M.; Pili, R.; Sironi, E.; Somenzi, G.; Ghidoni, R.; Toma, S.; Nicolò, G.; Sacchi, N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002, 62, 2455–2461.
28. Burbee, D.G.; Forgacs, E.; Zochbauer-Muller, S.; Shivakumar, L.; Fong, K.; Gao, B.; Randle, D.; Kondo, M.; Virmani, A.; Bader, S. et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 2011, 93, 691–699.
29. Agathanggelou, A.; Honorio, S.; Macartney, D.P.; Martinez, A.; Dallol, A.; Rader, J.; Fullwood, P.; Chauhan, A.; Walker, R.; Shaw, J.A. et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20, 1509–1518.
30. Si, S.P.; Lee, X.; Tsou, H.C.; Buchsbaum, R.; Tibaduiza, E.; Peacocke, M. RAR beta 2-mediated growth inhibition in HeLa cells. Exp. Cell Res. 1996, 223, 102–111.
31. Swisshelm, K.; Ryan, K.; Lee, X.; Tsou, H.C.; Peacocke, M.; Sager, R. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 1994, 5, 133–141.
32. Liu, Y.; Lee, M.O.; Wang, H.G.; Li, Y.; Hashimoto, Y.; Klaus, M.; Reed, J.C.; Zhang, X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 1996, 16, 1138–1149.
33. Rabizadeh, S.; Xavier, R.J.; Ishiguro, K.; Bernabeortiz, J.; Lopez-Ilasaca, M.; Khokhlatchev, A.; Mollahan, P.; Pfeifer, G.P.; Avruch, J.; Seed, B. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J. Biol. Chem. 2004, 279, 29247–29254.
34. Ortiz-Vega, S.; Khokhlatchev, A.; Nedwidek, M.; Zhang, X.F.; Dammann, R.; Pfeifer, G.P.; Avruch, J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002, 21, 1381–1390.
35. Song, M.S.; Song, S.J.; Kim, S.Y.; Oh, H.J.; Lim, D.S. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008, 27, 1863–1874.
36. Liu, L.; Vo, A.; McKeehan, W.L. Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5. Cancer Res. 2005, 65, 1830–1838.
37. Vassilomanolakis, M.; Koumakis, G.; Barbounis, V.; Demiri, M.; Pateras, H.; Efremidis, A.P. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann. Oncol. 2000, 11, 1155–1160.
38. Nole, F.; Munzone, E.; Mandala, M.; Catania, C.; Orlando, L.; Zampino, M.G.; Minchella, I.; Colleoni, M.; Peruzzotti, G.; Marrocco, E. et al. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. Ann. Oncol. 2001, 12, 95–100.
39. Dixit, M.; Yang, J.L.; Poirier, M.C.; Price, J.O.; Andrews, P.A.; Arteaga, C.L. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. 1997, 89, 365–373.
40. Sakakura, C.; Sweeney, E.A.; Shirahama, T.; Igarashi, Y.; Hakomori, S.; Tsujimoto, H.; Imanishi, T.; Ogaki, M.; Ohyama, T.; Yamazaki, J. et al. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Surg. Today 1997, 27, 676–679.
41. Blanc, C.; Deveraux, Q.L.; Krajewski, S.; Janicke, R.U.; Porter, A.G.; Reed, J.C.; Jaggi, R.; Marti, A. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res. 2000, 60, 4386–4390.
42. Thomadaki, H.; Scorilas, A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann. N. Y. Acad. Sci. 2007, 1095, 35–44.
43. Yang, M.; Yuan, F.; Li, P.; Chen, Z.; Chen, A.; Li, S.; Hu, C. Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells. Mol. Cancer 2012, 11, 54.
44. Shiu, L.Y.; Chang, L.C.; Liang, C.H.; Huang, Y.S.; Sheu, H.M.; Kuo, K.W. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem. Toxicol. 2007, 45, 2155–2164.
45. Schneider, B.G.; Peek, R.J. Gastric cancer prevention by demethylation. Cancer Prev. Res. 2013, 6, 253–256.
46. Majid, S.; Dar, A.A.; Saini, S.; Shahryari, V.; Arora, S.; Zaman, M.S.; Chang, I.; Yamamura, S.; Tanaka, Y.; Chiyomaru, T. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res. 2013, 19, 73–84.
47. Shin, H.; Kim, J.H.; Lee, Y.S.; Lee, Y.C. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: Induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Int. J. Oncol. 2012, 40, 1533–1542.
48. Liu, J.; Xie, Y.S.; Wang, F.L.; Zhang, L.J.; Zhang, Y.; Luo, H.S. Cytotoxicity of 5-aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A). Biomed. Pharmacother. 2013, 67, 78–87.
49. Singh, K.P.; Treas, J.; Tyagi, T.; Gao, W. DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells. Cancer Lett. 2012, 316, 62–69.
50. Seewaldt, V.L.; Johnson, B.S.; Parker, M.B.; Collins, S.J.; Swisshelm, K. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 1995, 6, 1077–1088.
51. Levesley, J.; Lusher, M.E.; Lindsey, J.C.; Clifford, S.C.; Grundy, R.; Coyle, B. RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol. 2011, 13, 1265–1276.
52. Yi, M.; Yang, J.; Chen, X.; Li, J.; Li, X.; Wang, L.; Tan, Y.; Xiong, W.; Zhou, M.; McCarthy, J.B. et al. RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J. Cell Physiol. 2011, 226, 2360–2369.
53. Matallanas, D.; Romano, D.; Yee, K.; Meissl, K.; Kucerova, L.; Piazzolla, D.; Baccarini, M.; Vass, J.K.; Kolch, W.; OʼNeill, E. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 2007, 27, 962–975.
54. Dammann, R.; Yang, G.; Pfeifer, G.P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 2011, 61, 3105–3109.
55. Niknafs, B. Induction of apoptosis and non-apoptosis in human breast cancer cell line (MCF-7) by cisplatin and caffeine. Iran. Biomed. J. 2011, 15, 130–133.
56. Mir, R.; Tortosa, A.; Martinez-Soler, F.; Vidal, A.; Condom, E.; Perez-Perarnau, A.; Ruiz-Larroya, T.; Gil, J.; Giménez-Bonafé, P. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int. J. Cancer 2013, 132, 1525–1536.
57. Chu, F.; Barkinge, J.; Hawkins, S.; Gudi, R.; Salgia, R.; Kanteti, P.V. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: Effect of elevated levels of BCL-2. Cancer Res. 2005, 65, 5301–5309.
58. Yoshida, Y.; Hosokawa, K.; Dantes, A.; Tajima, K.; Kotsuji, F.; Amsterdam, A. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Int. J. Oncol. 2000, 17, 227–235.
59. Cho, N.Y.; Kim, B.H.; Choi, M.; Yoo, E.J.; Moon, K.C.; Cho, Y.M.; Kim, D.; Kang, G.H. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol. 2007, 211, 269–277.
60. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.V.; Laird, P.W. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28, E32.
61. Farias, E.F; Arapshian, A.; Bleiweiss, I.J.; Waxman, S.; Zelent, A.; Mira-Y-Lopez, R. Retinoic acid receptor alpha2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ. 2002, 13, 335–341.
62. Yan, P.S.; Shi, H.; Rahmatpanah, F.; Hsiau, T.H.; Hsiau, A.H.; Leu, Y.W.; Liu, J.C.; Huang, T.H. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res. 2003, 63, 6178–6186.
63. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408.